Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Chevreau · SciRah

Researcher profile · Semantic Scholar

C. Chevreau

Share profile

C. Chevreau — researcher profile on SciRah

h-index: 71
Works: 419
Citations: 27K

Most-cited papers

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
T. Choueiri, P. Tomczak, S. Park, B. Venugopal +29 more
2021New England Journal of Medicine608 citations Open access
Semantic Scholar
Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-Term Follow-up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial
R. Motzer, B. Escudier, S. George, H. Hammers +27 more
2020Cancer292 citations Open access
Semantic Scholar
Cabozantinib in Advanced Ewing Sarcomas and osteosarcomas: a multicentre, single-arm, phase 2 trial
A. Italiano, O. Mir, S. Mathoulin-Pélissier, N. Penel +18 more
2020The Lancet Oncology261 citations Open access
Semantic Scholar
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
A. Italiano, A. Bessede, M. Pulido, E. Bompas +17 more
2022Nature Medicine250 citations
Semantic Scholar
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +8 more
2022Journal of Clinical Oncology163 citations
Semantic Scholar
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
A. Méjean, A. Ravaud, S. Thézénas, C. Chevreau +20 more
2021European Urology119 citations Open access
Semantic Scholar
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Y. Vano, R. Elaidi, M. Bennamoun, C. Chevreau +38 more
2022The Lancet Oncology108 citations Open access
Semantic Scholar
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
P. Pautier, A. Italiano, S. Piperno-Neumann, C. Chevreau +16 more
2022The Lancet Oncology99 citations Open access
Semantic Scholar
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +8 more
2023The Lancet Oncology77 citations Open access
Semantic Scholar
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
S. Négrier, N. Rioux-Leclercq, C. Ferlay, M. Gross-Goupil +12 more
2020European Journal of Cancer49 citations Open access
Semantic Scholar
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
F. Duffaud, A. Italiano, E. Bompas, M. Ríos +19 more
2021European Journal of Cancer45 citations Open access
Semantic Scholar
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Y. Loriot, M. Texier, S. Culine, A. Flechon +16 more
2022European Urology40 citations Open access
Semantic Scholar
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
M. Gounder, A. Razak, N. Somaiah, S. Chawla +67 more
2022Journal of Clinical Oncology39 citations Open access
Semantic Scholar
Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
G. Spierenburg, P. Grimison, C. Chevreau, S. Stacchiotti +13 more
2022European Journal of Cancer34 citations Open access
Semantic Scholar
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
A. Le Cesne, J. Blay, D. Cupissol, A. Italiano +20 more
2021Annals of Oncology34 citations Open access
Semantic Scholar
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
F. Duffaud, J. Blay, A. Le Cesne, C. Chevreau +16 more
2023British Journal of Cancer33 citations Open access
Semantic Scholar
Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group.
A. Crombé, M. Kind, I. Ray-Coquard, N. Isambert +10 more
2020AJR. American journal of roentgenology33 citations
Semantic Scholar
Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial
S. Bonvalot, N. Cozic, A. Le Cesne, J. Blay +12 more
2023Annals of Surgical Oncology29 citations
Semantic Scholar
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
C. Vauchier, É. Auclin, P. Barthélémy, L. Carril-Ajuria +18 more
2022Journal of Oncology29 citations Open access
Semantic Scholar
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
P. Pautier, A. Floquet, C. Chevreau, N. Penel +17 more
2021ESMO Open29 citations Open access
Semantic Scholar
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
P. Barthélémy, N. Rioux-Leclercq, C. Thibault, C. Saldana +9 more
2021Cancer Treatment Reviews28 citations Open access
Semantic Scholar
LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial
Y. Vano, R. Elaidi, M. Bennamoun, C. Chevreau +16 more
202028 citations Open access
Semantic Scholar
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
J. Courcier, C. Dalban, B. Laguerre, S. Ladoire +17 more
2021European Urology24 citations Open access
Semantic Scholar
Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
M. Debaudringhien, J. Blay, A. Bimbai, S. Bonvalot +16 more
2022ESMO Open23 citations Open access
Semantic Scholar
Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis.
N. Penel, S. Bonvalot, A. Bimbai, A. Meurgey +16 more
2022Clinical Cancer Research22 citations
Semantic Scholar
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
C. Thibault, A. Flechon, L. Albiges, C. Joly +15 more
2023European Journal of Cancer21 citations Open access
Semantic Scholar
Determinants of the access to remote specialised services provided by national sarcoma reference centres
Y. Fayet, R. Tétreau, C. Honoré, L. Le Nail +33 more
2021BMC Cancer21 citations Open access
Semantic Scholar
A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib.
N. Penel, O. Mir, J. Wallet, I. Ray-Coquard +16 more
2020European Journal of Cancer21 citations Open access
Semantic Scholar
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
L. Carril-Ajuria, P. Lavaud, C. Dalban, Sylvie Négrier +18 more
2024European Journal of Cancer20 citations Open access
Semantic Scholar
PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.
A. Italiano, A. Bessede, E. Bompas, S. Piperno-Neumann +12 more
202119 citations
Semantic Scholar
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors
Camille Azam, Pauline Claraz, C. Chevreau, Camille Vinson +10 more
2020European Journal of Clinical Pharmacology19 citations
Semantic Scholar
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
C. Moreau-Bachelard, L. Campion, M. Toulmonde, A. Le Cesne +19 more
2022ESMO Open18 citations Open access
Semantic Scholar
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
E. Rassy, C. Dalban, E. Colomba, L. Derosa +16 more
2022Clinical Genitourinary Cancer18 citations Open access
Semantic Scholar
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
A. Le Cesne, C. Chevreau, C. Perrin, A. Italiano +15 more
2023ESMO Open16 citations Open access
Semantic Scholar
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
M. Velev, C. Dalban, C. Chevreau, G. Gravis +23 more
2023European Journal of Cancer16 citations Open access
Semantic Scholar
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial
K. Fizazi, G. Le Teuff, A. Fléchon, L. Pagliaro +16 more
2024Journal of Clinical Oncology14 citations
Semantic Scholar
Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
M. de Vries-Brilland, N. Rioux-Leclercq, M. Meylan, J. Dauvé +15 more
2023Journal for ImmunoTherapy of Cancer14 citations Open access
Semantic Scholar
LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
P. Pautier, A. Italiano, S. Piperno-Neumann, C. Chevreau +16 more
2021Annals of Oncology14 citations Open access
Semantic Scholar
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
S. Culine, V. Harter, C. Krucker, G. Gravis +9 more
2023Cancers12 citations Open access
Semantic Scholar
An enhancer demethylator phenotype converged to immune dysfunction and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomas.
Xiao-Fan Lu, Y. Vano, Alexandra Helleux, Xiaoping Su +21 more
2022Clinical Cancer Research11 citations Open access
Semantic Scholar
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
S. Culine, V. Harter, G. Gravis, A. Flechon +27 more
2021Clinical Genitourinary Cancer11 citations Open access
Semantic Scholar
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
F. Puisset, Mourad Mseddi, L. Mourey, D. Pouessel +3 more
2023Cancers10 citations Open access
Semantic Scholar
1913O A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
P. Pautier, A. Italiano, S. Piperno-Neumann, C. Chevreau +15 more
2023Annals of Oncology10 citations Open access
Semantic Scholar
The SEMITEP trial: De-escalating chemotherapy in low-volume metastatic seminoma based on early FDG-PET.
Y. Loriot, M. Texier, S. Culine, A. Flechon +15 more
202010 citations
Semantic Scholar
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk.
T. Powles, R. Motzer, L. Albiges, C. Suárez +10 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +8 more
2021Annals of Oncology9 citations Open access
Semantic Scholar
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).
M. Cancel, G. Fromont, C. Blonz, C. Chevreau +20 more
2021European Journal of Cancer9 citations Open access
Semantic Scholar
Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.
P. Lavaud, C. Dalban, S. Négrier, C. Chevreau +15 more
2020Journal of Clinical Oncology7 citations
Semantic Scholar
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
C. Pfister, G. Gravis, A. Flechon, C. Chevreau +7 more
2023Journal of Clinical Oncology6 citations Open access
Semantic Scholar
657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
L. Derosa, C. A. C. Silva, C. Dalban, E. Colomba +16 more
2021Annals of Oncology6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Gravis×20
Invite
G. Gravis — researcher profile on SciRah
B. Laguerre×20
Invite
B. Laguerre — researcher profile on SciRah
E. Bompas×17
Invite
E. Bompas — researcher profile on SciRah
S. Piperno-Neumann×16
Invite
S. Piperno-Neumann — researcher profile on SciRah

M. Gross-Goupil

×15

Invite

M. Gross-Goupil — researcher profile on SciRah

Invite

S. Oudard — researcher profile on SciRah

Invite

N. Penel — researcher profile on SciRah

P. Barthélémy×14

Invite

P. Barthélémy — researcher profile on SciRah

A. Le Cesne×14

Invite

A. Le Cesne — researcher profile on SciRah

A. Italiano×13

Invite

A. Italiano — researcher profile on SciRah

Invite

F. Duffaud — researcher profile on SciRah

Invite

J. Blay — researcher profile on SciRah